Linked Life Data

1916490

Source:http://linkedlifedata.com/resource/pubmed/id/1916490

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1991-11-8
pubmed:abstractText
Since pancreatobiliary diversion probably stimulates pancreatic growth by increasing cholecystokinin secretion, the effect of the cholecystokinin antagonist CR-1409 on this adaptive response was tested. Male Wistar rats (n = 108) weighing 220-250g were randomised to receive either pancreatobiliary diversion (n = 60) or sham diversion (n = 48) and thereafter to receive either saline injections or CR-1409 (10 mg/kg/day, subcutaneously). Rats were killed at four, seven, and 14 days postoperatively, when blood was obtained for cholecystokinin assay and the pancreas was assessed for proliferative activity by three techniques: nucleic acid and protein assay, bromodeoxyuridine labelling, and metaphase arrest after vincristine administration (1 mg/kg, intraperitoneally). Pancreatobiliary diversion increased plasma cholecystokinin concentrations by 91% at seven days and 137% at 14 days, irrespective of CR-1409 treatment. Total pancreatic RNA content was doubled by pancreatobiliary diversion at four days (2.15 v 1.07 mg/100 g body weight: p less than 0.001) and at seven days (3.43 v 1.76 mg/100 g: p less than 0.001), and trebled at 14 days (4.27 v 1.32 mg/100 g: p less than 0.001). Pancreatobiliary diversion increased bromodeoxyuridine labelling index from 1.1 to 3.7% at seven days and the cell birth rate from 0.09 to 0.06%. CR-1409 completely abolished this proliferative response and partly prevented the rise in RNA. The results confirm pancreatic hypertrophy and increased acinar cell proliferation after pancreatobiliary diversion. CR-1409 prevents this adaptive growth, probably by blocking cholecystokinin receptors. Bromodeoxyuridine labelling and the metaphase arrest technique may be used to assess pancreatic cell kinetics.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-1130678, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-13673321, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-1989667, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-2105911, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-2409582, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-2446964, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-2450798, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-2473146, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-2682603, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-2818422, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-3692304, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-3692316, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-3692317, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-3793725, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-3841330, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-6008008, http://linkedlifedata.com/resource/pubmed/commentcorrection/1916490-6468769
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0017-5749
pubmed:author
pubmed:issnType
Print
pubmed:volume
32
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1049-54
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Inhibitory effect of a cholecystokinin antagonist on the proliferative response of the pancreas to pancreatobiliary diversion.
pubmed:affiliation
Department of Surgery, Postgraduate Medical School, Hammersmith Hospital, London.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't